If you live in Europe, you may never have heard of 'neglected diseases' from Trypanosomatidic infections. However, in countries like Brazil or Sudan these diseases are endemic.
Neglected diseases are conditions that inflict severe health burdens on the world's poorest people, and they are said to be 'neglected' because they are often overlooked by drug developers. Leishmaniasis, sleeping sickness and chagas disease represent a huge problem in the lives of people who are affected. Existing drugs to treat them are simply inadequate, presenting problems like inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. Experts say that new drugs are urgently needed to address the problem.
NMTRYPI ('New Medicines for Trypanosomatidic Infections') a consortium of nine EU academic institutes and four SMEs, recently launched a programme to answer this call by optimising anti-trypanosomal drugs. The NMTRYPI partners are already well familiar with the anti-trypanosomal drugs in question because they were previously responsible for discovering them. Now, they will build on that work by attempting to progress the lead compounds in these drugs as well as screening fungal natural products and Sudanese medicinal plants to discover new lead compounds for development.
Over the next three years, NMTRYPI's interdisciplinary team will use a common drug discovery platform, established by experts in their respective fields, to develop drug leads which may be used in combination with other drugs. The partners will also work to develop pharmacodynamic biomarkers that enable the proteomic profiling of compound efficacy and early identification of drug resistance. The platform used by NMTRYPI enables high throughput screening of compound libraries, leads to candidate drugs development, proof of concept testing, and toxicology and safety testing. It will ultimately allow the NMTRYPI team to translate drug leads into drug candidates to enter the international drug development pipelines.
Neglected diseases like leishmaniasis, sleeping sickness and chagas disease are most prevalent in tropical climates, particularly in areas with unsafe drinking water, poor sanitation, sub-standard housing and little or no access to health care. Unfortunately, neglected diseases can often also lack visibility because they usually do not cause dramatic outbreaks that kill large numbers of people. Rather, they usually exact their toll over a longer period of time, leading to crippling deformities, severe disabilities and/or relatively slow deaths.
Explore further: Existing gold-based drug is toxic to 'Baghdad boil' infection
More information: For more information, see http://ift.tt/1nDfCYG
Medical Xpress on facebook
Related Stories
Existing gold-based drug is toxic to 'Baghdad boil' infection
Feb 24, 2014
A protozoan parasite that causes unhealing, potentially disfiguring skin sores appears to have a weakness for gold.
Open access initiative reveals drug hits for deadly neglected tropical diseases
Nov 13, 2012
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through ...
Three neglected-disease treatments newly added to WHO Essential Medicines List for paediatric use
Jul 11, 2013
This week the World Health Organization (WHO) released its newly updated 4th WHO Model List of Essential Medicines for Children (EMLc), in which three treatments developed by the Drugs for Neglected Diseases initiative (DNDi) ...
Deadly gaps persist in new drug development for neglected diseases
Oct 24, 2013
In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative (DNDi) and other researchers report a persistent deficiency in truly new therapeutics for neglec ...
Crowdfunding drug discovery
Oct 29, 2013
During his nine years working in the pharmaceutical industry, Michael Pollastri learned to protect his research and data with extreme caution. "In the drug industry, everything is super secret," said Pollastri, now an associate ...
Recommended for you
Dartmouth and Aeras join forces to conduct study of new tuberculosis vaccine
2 hours ago
Dartmouth's Geisel School of Medicine and Aeras, a global nonprofit biotech, announced a collaboration to jointly conduct a trial of a new vaccine against tuberculosis (TB), one of the world's deadliest diseases. The vaccine, ...
Tamiflu reduces risk of death by 25 percent in adults hospitalised with H1N1 pandemic influenza
11 hours ago
Adults hospitalised with H1N1 influenza during the 2009-2010 pandemic were 25% less likely to die from the disease if they were given antiviral drugs called neuraminidase inhibitors (NAIs) such as Tamiflu, according to a ...
Children with glomerular kidney disease more likely to have hypertension as adults
13 hours ago
Men who as children had glomerular disease, a disorder of the portion of the kidney that filters blood and one that usually resolves with time, were more likely than men without childhood glomerular disease to have high blood ...
Study examines use of age-adjusted D-dimer levels to exclude lung blood clots
13 hours ago
Using a patient's age to raise the threshold for an abnormal result of a blood test used to assess patients with a suspected pulmonary embolism (blood clot in lungs) appeared to be safe and led to fewer healthy patients with ...
Pregnancy associated with greater risk of certain bacterial infection, may worsen outcomes
13 hours ago
In a surveillance study of infection with the bacterium Haemophilus influenzae among women of reproductive age in England and Wales from 2009-2012, pregnancy was associated with a greater risk of this infection, which was as ...
One in three patients with bloodstream infections given inappropriate therapy
13 hours ago
Growing drug resistance, a high prevalence of S. aureus bacteria and ineffective antibiotics prescribed to one in three patients are among the challenges facing community hospitals in treating patients with serious bloods ...
User comments
© Medical Xpress 2011-2014, Science X network
If you live in Europe, you may never have heard of 'neglected diseases' from Trypanosomatidic infections. However, in countries like Brazil or Sudan these diseases are endemic.
Neglected diseases are conditions that inflict severe health burdens on the world's poorest people, and they are said to be 'neglected' because they are often overlooked by drug developers. Leishmaniasis, sleeping sickness and chagas disease represent a huge problem in the lives of people who are affected. Existing drugs to treat them are simply inadequate, presenting problems like inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. Experts say that new drugs are urgently needed to address the problem.
NMTRYPI ('New Medicines for Trypanosomatidic Infections') a consortium of nine EU academic institutes and four SMEs, recently launched a programme to answer this call by optimising anti-trypanosomal drugs. The NMTRYPI partners are already well familiar with the anti-trypanosomal drugs in question because they were previously responsible for discovering them. Now, they will build on that work by attempting to progress the lead compounds in these drugs as well as screening fungal natural products and Sudanese medicinal plants to discover new lead compounds for development.
Over the next three years, NMTRYPI's interdisciplinary team will use a common drug discovery platform, established by experts in their respective fields, to develop drug leads which may be used in combination with other drugs. The partners will also work to develop pharmacodynamic biomarkers that enable the proteomic profiling of compound efficacy and early identification of drug resistance. The platform used by NMTRYPI enables high throughput screening of compound libraries, leads to candidate drugs development, proof of concept testing, and toxicology and safety testing. It will ultimately allow the NMTRYPI team to translate drug leads into drug candidates to enter the international drug development pipelines.
Neglected diseases like leishmaniasis, sleeping sickness and chagas disease are most prevalent in tropical climates, particularly in areas with unsafe drinking water, poor sanitation, sub-standard housing and little or no access to health care. Unfortunately, neglected diseases can often also lack visibility because they usually do not cause dramatic outbreaks that kill large numbers of people. Rather, they usually exact their toll over a longer period of time, leading to crippling deformities, severe disabilities and/or relatively slow deaths.
Explore further: Existing gold-based drug is toxic to 'Baghdad boil' infection
More information: For more information, see http://ift.tt/1nDfCYG
Medical Xpress on facebook
Related Stories
Existing gold-based drug is toxic to 'Baghdad boil' infection
Feb 24, 2014
A protozoan parasite that causes unhealing, potentially disfiguring skin sores appears to have a weakness for gold.
Open access initiative reveals drug hits for deadly neglected tropical diseases
Nov 13, 2012
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through ...
Three neglected-disease treatments newly added to WHO Essential Medicines List for paediatric use
Jul 11, 2013
This week the World Health Organization (WHO) released its newly updated 4th WHO Model List of Essential Medicines for Children (EMLc), in which three treatments developed by the Drugs for Neglected Diseases initiative (DNDi) ...
Deadly gaps persist in new drug development for neglected diseases
Oct 24, 2013
In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative (DNDi) and other researchers report a persistent deficiency in truly new therapeutics for neglec ...
Crowdfunding drug discovery
Oct 29, 2013
During his nine years working in the pharmaceutical industry, Michael Pollastri learned to protect his research and data with extreme caution. "In the drug industry, everything is super secret," said Pollastri, now an associate ...
Recommended for you
Dartmouth and Aeras join forces to conduct study of new tuberculosis vaccine
2 hours ago
Dartmouth's Geisel School of Medicine and Aeras, a global nonprofit biotech, announced a collaboration to jointly conduct a trial of a new vaccine against tuberculosis (TB), one of the world's deadliest diseases. The vaccine, ...
Tamiflu reduces risk of death by 25 percent in adults hospitalised with H1N1 pandemic influenza
11 hours ago
Adults hospitalised with H1N1 influenza during the 2009-2010 pandemic were 25% less likely to die from the disease if they were given antiviral drugs called neuraminidase inhibitors (NAIs) such as Tamiflu, according to a ...
Children with glomerular kidney disease more likely to have hypertension as adults
13 hours ago
Men who as children had glomerular disease, a disorder of the portion of the kidney that filters blood and one that usually resolves with time, were more likely than men without childhood glomerular disease to have high blood ...
Study examines use of age-adjusted D-dimer levels to exclude lung blood clots
13 hours ago
Using a patient's age to raise the threshold for an abnormal result of a blood test used to assess patients with a suspected pulmonary embolism (blood clot in lungs) appeared to be safe and led to fewer healthy patients with ...
Pregnancy associated with greater risk of certain bacterial infection, may worsen outcomes
13 hours ago
In a surveillance study of infection with the bacterium Haemophilus influenzae among women of reproductive age in England and Wales from 2009-2012, pregnancy was associated with a greater risk of this infection, which was as ...
One in three patients with bloodstream infections given inappropriate therapy
13 hours ago
Growing drug resistance, a high prevalence of S. aureus bacteria and ineffective antibiotics prescribed to one in three patients are among the challenges facing community hospitals in treating patients with serious bloods ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment